A phase 2 trial has found a myostatin inhibitor reduces lean mass loss in patients receiving tirzepatide.
End of content
No more pages to load
A phase 2 trial has found a myostatin inhibitor reduces lean mass loss in patients receiving tirzepatide.
End of content
No more pages to load